Afshar-Oromieh A., Avtzi E., Giesel F.L., Holland-Letz T., Linhart H.G., Eder M., Eisenhut M., Boxler S., Hadaschik A., Kratochwill C., Weichert W., Kopka K., Debus J., Haberkorn U. The diagnostic value of PET/CT imaging with the [68Ga]-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015;42(2):197-209.
|
Cardinale J., Martin R., Remde Y., Schäfer M., Hienzsch A., Hübner S., Zerges A.-M., Marx H., Hesse R., Weber K. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals. 2017;10(4):77.
|
Cardinale J., Roscher M., Schäfer M., Geerlings M., Benešová M., Bauder-Wüst U., Remde Y., Eder M., Nováková Z., Motlová L., Barinka C., Giesel F.L., Kopka K. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors. J. Med. Chem. 2020; 63(19):10897–10907.
|
Culp M.B., Soerjomataram I., Efstathiou J.,Bray F. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. European Urology. 2020;77(1):38-52.
|
Eeles R., Ni Raghallaigh H. Men with a susceptibility to prostate cancer and the role of genetic based screening. Transl. Androl. Urol. 2018;7(1):61‐69.
|
Giesel FL., Hadaschik B., Cardinale J.,Radtke J., Vinsensia M.,Lehnert W., Kesch C., Tolstov Y., Singer S., Grabe N., Duensing S., Schäfer M., Neels O.C., Mier W., Haberkorn U., Kopka K., Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 2017;44(4):678-688.
|
Ioppolo J.A., Nezich R.A., Richardson K.L., Morandeau L., Leedman P., Price R.I. Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Applied Radiation and Isotopes 2020;161.
|
Katzschmann I., Marx H., Kopka K., Hennrich U. Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. Pharmaceuticals. 2021;14(3):188.
|
Kesch C., Kratochwil C., Mier W., Kopka K., Giesel FL. 68Ga or 18F for Prostate Cancer Imaging? J. Nucl. Med. 2017; 58(5):687-688.
|
Kuntzsch M., Lamparter D., Brüggener N., Müller M., Kienzle G. Development of Kryptofix 2.2.2 and Tetrabutylammonium in [18F]-labeled Radiopharmaceutical. Pharmaceuticals. 2014;(7):621-633.
|
Naka S., Watabe T., Kurimoto K., Uemura M., Soeda, F., Neels O.C., Kopka K., Tatsumi M., Kato H., Nonomura N., Shimosegawa E., Cardinale j., Giesel F.L., Hatazawa J. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. Eur. J. Nucl. Med. Mol. Imaging: Radiopharm. Chem. 2020;(5):18.
|
Shammi O., Nebeling B., Grievink H., Mishani E. Fine-tuning of the automated [18F]PSMA-1007. J.Label. Comp. Radiopharm. 2019;(62):252-258.
|
Sprute K., Kramer V., Koerber S.A., Meneses M., Fernandez R., Soza-Ried C., Eiber M., Weber W.A., Rauscher I., Rahbar K., Schaefers M., Watabe T., Uemura M., Naka S., Nonomura N., Hatazawa J., Schwab C., Schutz V., Hohenfellner M., Holland-Letz T., Debus J., Kratochwil C., Amaral H.,Choyke P.L., Haberkorn U., Sandoval C, Giesel F.L.
Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J. Nucl. Med 2021; (62):208-213.
|
Umbricht C.A., Benešová M., Schmid R.M., Türler A., Schibli R., Van der Meulen N., Müller C. [44Sc]‐PSMA‐617 for radiotheragnostics in tandem with [177Lu]‐PSMA‐617‐preclinical investigations in comparison with [68Ga]‐PSMA‐11 and [68Ga]‐PSMA‐617. Eur. J. Nucl. Med. Mol. Imaging. Res. 2017;7(1):9.
|
Werner R., Derlin T., Lapa C., Sheikbahaei S., Higuchi T., Giesel F., Behr S., Drzezga A., Kimura H., Buck A., Bengel F., Pomper M., Gorin M., Rowe S. [18F]-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. 2020;10(1):1-16.
|
Wurzer A., Di Carlo D., Schmidt A., Beck R., Eiber M., Schwaiger M., Jurgen Wester H. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by [18F]- or [68Ga]-Labeled rhPSMA Inhibitors. J. Nucl. Med. 2020;(61):735–742.
|
Zhou D., Lin M., Yasui N., Al-Qahtani M., Dence S., Schwarz S., Katzenellenbogen J. Optimization of the preparation of fluorine‐18‐labeled steroid receptor ligands 16alpha‐[18F] fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta‐[18F]fluoro‐5alpha‐dihydrotestosterone (FDHT) as radiopharmaceuticals. J. Labelled Comp. Radiopharm. 2014;57(5):371‐377.
|
Zippel C., Ronski S., Bohnet-Joschko S., Giesel F., Kopka K. Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. Pharmaceuticals (Basel). 2020;13(1):12.
|
Monograph “PSMA-1007 (18F) Injection” (Monograph Number: 07/2021:3116). European Pharmacopeia, 10th Edition. 2020. Available online: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition (accessed on 19 April 2021).
|